Mexico - Delayed Quote MXN

Bristol-Myers Squibb Company (BMY.MX)

925.00

-52.00

(-5.32%)

At close: April 24 at 7:59:49 AM CST

Netflix's new high, Bristol Myers outlook, Texas Instruments pops

As part of today's Market Minute, Brad Smith outlines some of the top stories of the trading session. Netflix (NFLX) stock hits a fresh all-time high, with some Wall Street analysts saying the stock is a recession-resistant play. Bristol Myers Squibb (BMY) lifts its outlook on strong sales driven by its cancer drug. Texas Instruments (TXN) stock pops after the company's earnings beat estimates amid what the CEO calls a "real recovery' for its industrials business. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 15 hours ago

NFLX

BMY

CELG-RT
Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.

Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.

Barrons.com 9 hours ago

CELG-RT
Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat

Bristol Myers Squibb stock reversed higher Thursday after the drugmaker beat first-quarter expectations and raised its outlook for the year.

Investor's Business Daily 11 hours ago

BMY

CELG-RT
Dividends Could Be Under Threat. Here Are 9 Stocks With Safe 5% Yields.

Goldman Sachs expects companies’ spending on dividends to increase less quickly in 2025 than it had forecast earlier.

Barrons.com 11 hours ago

SWK

^GSPC

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance

Bristol-Myers Squibb (NYSE:BMY) demonstrated a strong performance by shifting from a net loss to profit in Q1 2025, and increased its revenue guidance, reflecting confidence in its growth and legacy portfolios. However, despite these positive earnings and guidance revisions, Bristol-Myers saw a price movement of 2% downward over the past week, contrasting with a vibrant market that rose sharply by 2.3% due to favorable earnings reports across sectors and anticipation of tariff changes. The...

Simply Wall St. 13 hours ago

BMY

CELG-RT
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. Sales decreased 6% year-over-year, or 4% when adjusted for foreign exchange impacts. U.S. revenues of $7.9 billion decreased by 7%, and International revenues of $3.3 billion decreased by 2% or increased by 2% Ex-FX. Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos a

Benzinga 15 hours ago

CELG-RT
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook

BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.

Zacks 15 hours ago

CELG-RT
Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 17 hours ago

CELG-RT
Drugmakers brace for Trump tariffs, while weighing numerous other worries

(Reuters) -Major drugmakers were a standout on a tumultuous day of corporate earnings on Thursday, beating expectations even as they grapple with the threat of sector-specific tariffs, efforts to lower drug prices and federal layoffs that could undermine efforts to invest heavily in the U.S. in coming years. Bristol Myers Squibb, Merck & Co, Sanofi and Roche all exceeded quarterly earnings expectations on Thursday, and Bristol raised its profit forecast. Still, drugmakers are grappling with several factors that could cause upheaval, such as Trump administration efforts to shrink the federal workforce, including at the U.S. Food and Drug Administration, and probes into pharmaceutical imports that set the stage for levies on the sector.

Reuters 18 hours ago

ROG.SW

CELG-RT
Bristol Myers says schizophrenia drug launch ‘off to a solid start’

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily beating Wall Street expectations.

BioPharma Dive 19 hours ago

CELG-RT
Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates

Bristol Myers (BMY) delivered earnings and revenue surprises of 19.21% and 4.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 19 hours ago

CELG-RT
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s full-year revenue guidance of $46.3 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.80 per share was 19.9% above analysts’ consensus estimates.

StockStory 19 hours ago

CELG-RT
Bristol Myers: Q1 Earnings Snapshot

PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier. The Princeton, New Jersey-based company said it had profit of $1.20 per share. Earnings, adjusted for amortization costs and non-recurring costs, came to $1.80 per share.

Associated Press Finance 20 hours ago

CELG-RT
Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales

(Reuters) -Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer. The company's shares, which were off 1% in early trading on Thursday, have dropped more than 20% over the past month as investor concerns about U.S. President Donald Trump's tariff threats have roiled the markets. Chief Financial Officer David Elkins said in an interview that the company's global manufacturing footprint puts it in a good position to deal with whatever tariffs may come.

Reuters 20 hours ago

CELG-RT
Bristol Myers Squibb Reports First Quarter Financial Results for 2025

PRINCETON, N.J., April 24, 2025--Bristol Myers Squibb Reports First Quarter Financial Results for 2025

Business Wire 20 hours ago

BMY

CELG-RT
These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More

Tesla stock rises as CEO Elon Musk says in May he’ll be cutting back ’significantly’ his work with the Trump administration’s Department of Government Efficiency.

Barrons.com yesterday

BA

ENPH

TSLA
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.

Zacks yesterday

REGN

CELG-RT
Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook

Cobenfy failed to show statistically significant improvement as an adjunctive treatment for schizophrenia, the company said in a statement.

Barrons.com yesterday

CELG-RT
Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best stocks that will always grow. The Looming Risk of a Recession in the US Threats of an impending recession are looming over […]

Insider Monkey yesterday

CELG-RT
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. In the Phase 3 trial, adjunctive Cobenfy treatment demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo with an atypical antipsycho

Benzinga yesterday

CELG-RT

Performance Overview

Return	BMY.MX	S&P 500 (^GSPC)
YTD	-22.69%	-6.75%
1-Year	+11.23%	+8.15%
3-Year	-39.62%	+28.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company (BMY.MX)

Netflix's new high, Bristol Myers outlook, Texas Instruments pops

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy.

Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat

Dividends Could Be Under Threat. Here Are 9 Stocks With Safe 5% Yields.

Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance

Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact

BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

Drugmakers brace for Trump tariffs, while weighing numerous other worries

Bristol Myers says schizophrenia drug launch ‘off to a solid start’

Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates

Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations

Bristol Myers: Q1 Earnings Snapshot

Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales

Bristol Myers Squibb Reports First Quarter Financial Results for 2025

These Stocks Moved the Most Today: Tesla, Intel, Enphase, Bristol Myers, Boeing, AT&T, and More

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

Bristol Myers Stock Falls As Schizophrenia Trial Failure Dims Outlook

Is Bristol-Myers Squibb Company (BMY) the Best Stock That Will Always Grow?

Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides

Performance Overview